Evidence map›Paper›PMID 41569194›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2026

Prognostic and Predictive Significance of Cancer Stem Cell Markers (ZIP-4 and ALDH1A1) in Ovarian Serous Carcinoma Patients: An Immunohistochemical Study.

Amany Selim Attia, Mohamed Abdalsalam, Ahmed S E M Iraki, Samia Hussein, Ahmad Barakat Waley, Amr Khalil, Zahraa I Aboafya, Reham Sameh

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Amany Selim AttiaDepartment of Pathology, Faculty of Medicine, Zagazig University, Sharkia, Egypt.
Mohamed AbdalsalamDepartment of Obstetrics& Gynaecology, Al-Ahrar Teaching Hospital, Sharkia, Egypt.
Ahmed S E M IrakiDepartment of Obstetrics& Gynaecology, Faculty of Medicine, Zagazig University, Sharkia, Egypt.
Samia HusseinDepartment of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Zagazig University, Sharkia, Egypt.
Ahmad Barakat WaleyDepartment of Medical Oncology, Faculty of Medicine, Zagazig University, Sharkia, Egypt.
Amr KhalilDepartment of Surgical Oncology, Al-Ahrar Teaching Hospital, General Organization for Teaching Hospitals and Institutes (GOTHI), Egypt.
Zahraa I AboafyaDepartment of Clinical and Chemical Pathology, Institute of Medical Research and Clinical Studies, National Research Centre, Cairo, Egypt.
Reham SamehDepartment of Pathology, Faculty of Medicine, Zagazig University, Sharkia, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWorldwide, ovarian cancer is the eighth most common cancer among females and the fifth leading cause of cancer-related deaths in women. In Egypt, it accounts for 4.5% of all cancer cases and ranks the fourth most common cancer among women. Cancer stem cells (CSCs) play a crucial role in tumor growth and chemoresistance. Our study examined the expression of cancer stem cell markers (ZIP-4 and aldehyde dehydrogenase-1 member A1 (ALDH1A1)) in ovarian serous carcinoma tissues using immunohistochemistry. We also analyzed the relationship between their expression levels and clinicopathological features, patient survival, and response to platinum-based chemotherapy. SUBJECTS &

methodThis study included 55 patients with ovarian serous carcinoma.  Immunohistochemical staining for ZIP-4 and ALDH1A1 was performed.

resultsStatistically significant relationships were detected between high ZIP-4 and ALDH1A1 expressions and patient age, tumor size, presence of malignant ascites, lymphovascular invasion, elevated cancer antigen-125 (CA-125) levels, disease stage, and lymph node involvement (P < 0.001 for each). Additionally, the log-rank test showed that high ZIP-4 and ALDH1A1 expressions were associated with shorter disease-free survival (DFS) (P = 0.002 and <0.001, respectively) and overall survival (OS) (P < 0.001 for each).

conclusionOvarian cancer stem cell markers (ZIP-4 and ALDH1A1) can be considered potential prognostic markers in ovarian cancer patients. Moreover, ZIP-4 and ALDH1A1 expressions are related to resistance to platinum-based chemotherapy, which leads to ovarian serous carcinoma progression. Clinical implications suggest that future therapeutic regimens targeting ZIP-4 and ALDH1A1 may help overcome platinum-based chemotherapy resistance and improve patients outcomes.

Indexed as

Aldehyde DehydrogenaseBiomarkers, TumorCystadenocarcinoma, SerousNeoplastic Stem CellsOvarian NeoplasmsRetinal DehydrogenaseAdultAgedAldehyde Dehydrogenase 1 FamilyAntineoplastic Combined Chemotherapy ProtocolsFemaleFollow-Up StudiesHumansImmunohistochemistryMiddle AgedPrognosisAldehyde DehydrogenaseAldehyde Dehydrogenase 1 FamilyALDH1A1 protein, humanBiomarkers, TumorRetinal DehydrogenaseCancer stem cellsimmunohistochemistryOvarian Cancer

Identifiers

PMID41569194
PMCPMC13420504

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.